ArticleFrontiers in antibiotics2026
Linezolid MIC creep among clinically significant
Article in Frontiers in antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The rising threat of antimicrobial resistance, particularly the phenomenon of MIC creep, poses a significant challenge to the clinical effectiveness of key antibiotics. Linezolid is a crucial last-resort agent for treating severe infections caused by Gram-positive pathogens, including methicillin-resistant Methods: A retrospective study was conducted on clinical Results: From 2017 to 2024, A total of 4,325 Conclusion: Linezolid continues to be highly effective; however, the progressive MIC creep from 1 µg/mL to 2 µg/mL indicates emerging reduced susceptibility. These findings stress the need for ongoing MIC surveillance and strict antibiotic stewardship to preserve linezolid efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.